What is the typical Semax dose?
Preclinical Semax research protocols typically use 50-500 mcg per dose with intranasal administration as the dominant route. The intranasal-delivery framework reflects the compound’s developmental context as an intranasally-administered cognitive-research peptide.
What the research literature says
The Semax dose framework derives from the Russian-research-group literature that anchors the compound’s published research base. The Dolotov plasma-membrane-binding and biodegradation work (PMID 15344653) and the BDNF/TrkB-regulation work (PMID 16996037) characterised the dose-response and pharmacokinetic framework that supports the intranasal-delivery research protocols.
The Glazova fluvoxamine-exposure work extended the framework into developmental-research contexts (PMID 33418449). Across these studies the dose tiers are in the low-microgram-per-dose range with administration framed by the intranasal route to maximise central-nervous-system delivery.
Like Selank, Semax is approved for clinical use in the Russian Federation. The Western-regulator approval context is absent; research-supply protocols anchor to the published preclinical and Russian-clinical-research framework.
Why this matters in research context
Semax’s dose framework reflects the intranasal-administration developmental context. Researchers selecting Semax for cognitive-research protocols should anchor protocol design to the published intranasal-delivery framework; subcutaneous administration is less well-characterised and may produce different pharmacokinetic profiles than the published research literature would predict.
Related compounds
- Semax 10mg — the compound covered by this answer
Related research questions
References
- Dolotov OV et al. The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Bioorg Khim 2004;30(3):241-246. [PMID 15344653]
- Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006;1117(1):54-60. [PMID 16996037]
- Glazova NY et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides 2021;86:102114. [PMID 33418449]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semax is sold strictly as a research-grade reagent for laboratory and bench research applications.